Find It®
Tailor treatment decisions based on somatic mutations in your patient’s tumor.
At Canexia Health, we make high-quality cancer genomic information accessible and affordable with our clinically-validated assays, informatics, and support.
Solutions that drive precision oncology
Do More for Your Patients
Only a small percentage of cancer patients receive genomic biomarker testing that could match them with targeted treatments demonstrated to improve outcomes. We pair the latest advances in oncology with machine learning to provide cancer professionals with the insights needed to make targeted treatment decisions for their patients.
Our Solutions
Follow It®
A minimally invasive option for biopsy, Follow It can also be used to monitor cancer progression or investigate treatment resistance.
Fusions
Rapid, cost-effective, and clinically actionable, Fusions allows you the flexibility to isolate and interrogate relevant fusions.
Canexia Informatics Platform
Make more informed treatment decisions by using detailed results for therapeutic recommendations and expertly curated clinical trials information provided in our comprehensive reporting software.
Your Labs, Our Technology
Conduct world-leading mutation assays for cancer patients, right from your laboratory. Our cloud-based analytics platform allows partner labs access to our proprietary informatics software suite covering the full stack of molecular and computational quality assurance, genome analytics, mutation interpretation, and report generation.
Our Partners
“We have found the FIND-IT assay to be a reliable, quick and cost-effective tool for identifying driver mutations in fixed tissue samples from across Australia. This has had direct implications for identifying patients suitable for targeted therapies, especially those with lung cancer, colorectal cancer and melanoma. However, the scope of the test is such that there is also interest in the panel for patients with a variety of other cancers, including breast and endometrial cancers.” Professor Graeme Suthers, Sonic Genetics
Recent Resources
Blog
March 2, 2021
Assessing the Real World Accuracy of ctDNA Diagnostics
Canexia Health's Chief Scientific Officer writes about the importance of combining different approaches to obtain correct results for ctDNA diagnostics. While high sensitivity is important, it must be contextualized with other key measurements.
Blog
February 17, 2021
How 3 organizations are tackling disparities in cancer care
Before COVID-19 lockdowns halted travel, I attended a community cancer conference in Washington D.C. last year. I had an interesting conversation with a community practice leader, Jessica, about how socioeconomic factors have a big impact on clinical outcomes. In the last few months, I have been researching value-based care innovations in cancer care. I was encouraged to find multiple examples of value-based care initiatives that also focus on reducing disparities. How are they approaching challenges of inequity in cancer care? Here are three initiatives with innovative approaches.
In the News
February 4, 2021
Pilot of new cancer test in Canada shows promise as faster alternative to conventional biopsies
The COVID-19 pandemic has delayed thousands of surgical procedures across the country, including tissue biopsies needed for cancer diagnosis. But it’s also pushing demand for alternatives that allow patients to be tested for signs of tumours without even needing to enter a hospital. As part of a new pilot called Project ACTT, more than 800 Canadian cancer patients have been tested through liquid biopsies, which involve taking a blood sample and looking for signs of tumour DNA. That federally funded project, a partnership led by Vancouver-based Canexia Health, offers the potential for a more efficient alternative for cancer testing that can save hospital resources and lower the risk of infection.
Advance your cancer genomic testing with Canexia Health.
Canexia Health’s clinically-validated and cost-effective assays, informatics, and support offer a complete end-to-end solution, from mutation identification to auto-generated clinical reports.